Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call



Pharmacyclics Announces Date of Financial Results for Three Months Ended March
                         31, 2013 and Conference Call

PR Newswire

SUNNYVALE, Calif., April 24, 2013

SUNNYVALE, Calif., April 24, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the
"Company") (Nasdaq: PCYC) today announced that it will report financial
results and recent developments for its three months ended March 31, 2013
after the NASDAQ Market closes on Wednesday, May 1, 2013.  The Company will
conduct a conference call and audio webcast at 4:30 p.m ET on the same day. As
previously announced, the Company changed its fiscal year end from June 30 to
December 31, effective December 31, 2012. As a result, the three months ended
March 31, 2013 represents the Company's fiscal 2013 first quarter.

Conference call and webcast details:

Date: May 1, 2013
Time: 4:30 PM ET
Listen via Internet: http://ir.pharmacyclics.com/events.cfm
Toll-free: (877)-407-0778
International: (201)-689-8565

Replay Number (Toll Free): (877)-660-6853
Replay Number (International): (201)-612-7415
Conference ID #: 413317

A webcast replay will be available on the Pharmacyclics website for 30 days.

About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on
developing and commercializing innovative small-molecule drugs for the
treatment of cancer and immune mediated diseases. Our mission and goal is to
build a viable biopharmaceutical company that designs, develops and
commercializes novel therapies intended to improve quality of life, increase
duration of life and resolve serious unmet medical healthcare needs; and to
identify promising product candidates based on scientific development and
administrational expertise, develop our products in a rapid, cost-efficient
manner and pursue commercialization and/or development partners when and where
appropriate.

Presently, Pharmacyclics has three product candidates in clinical development
and several preclinical molecules in lead optimization. The Company is
committed to high standards of ethics, scientific rigor, and operational
efficiency as it moves each of these programs to viable commercialization.
The Company is headquartered in Sunnyvale, California and is listed on NASDAQ
under the symbol PCYC. To learn more about how Pharmacyclics advances science
to improve human healthcare visit us at http://www.pharmacyclics.com.

SOURCE Pharmacyclics, Inc.

Website: http://www.pharmacyclics.com
Contact: Joshua T. Brumm, Executive Vice President, Finance, +1-408-215-3311,
or Ramses Erdtmann, SVP Investor Relations & Administration, +1-408-215-3325
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement